Literature DB >> 33514585

Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.

Mahmut Akgul1, Sean R Williamson2, Dilek Ertoy3, Pedram Argani4, Sounak Gupta5, Anna Caliò6, Victor Reuter7, Satish Tickoo7, Hikmat A Al-Ahmadie8, George J Netto9, Ondrej Hes10,11, Michelle S Hirsch12, Brett Delahunt13, Rohit Mehra14, Stephanie Skala14, Adeboye O Osunkoya15, Lara Harik15, Priya Rao16, Ankur R Sangoi17, Maya Nourieh18, Debra L Zynger19, Steven Cristopher Smith20, Tipu Nazeer21, Berrak Gumuskaya22, Ibrahim Kulac3, Francesca Khani23, Maria S Tretiakova24, Funda Vakar-Lopez24, Guliz Barkan25, Vincent Molinié26, Virginie Verkarre27, Qiu Rao28, Lorand Kis29, Angel Panizo30, Ted Farzaneh31, Martin J Magers32, Joseph Sanfrancesco33, Carmen Perrino34, Dibson Gondim35, Ronald Araneta36, Jeffrey S So37, Jae Y Ro38, Matthew Wasco39, Omar Hameed40, Antonio Lopez-Beltran41, Hemamali Samaratunga42, Sara E Wobker43, Jonathan Melamed44, Liang Cheng45, Muhammad T Idrees45.   

Abstract

Transcription factor E3-rearranged renal cell carcinoma (TFE3-RCC) has heterogenous morphologic and immunohistochemical (IHC) features.131 pathologists with genitourinary expertise were invited in an online survey containing 23 questions assessing their experience on TFE3-RCC diagnostic work-up.Fifty (38%) participants completed the survey. 46 of 50 participants reported multiple patterns, most commonly papillary pattern (almost always 9/46, 19.5%; frequently 29/46, 63%). Large epithelioid cells with abundant cytoplasm were the most encountered cytologic feature, with either clear (almost always 10/50, 20%; frequently 34/50, 68%) or eosinophilic (almost always 4/49, 8%; frequently 28/49, 57%) cytology. Strong (3+) or diffuse (>75% of tumour cells) nuclear TFE3 IHC expression was considered diagnostic by 13/46 (28%) and 12/47 (26%) participants, respectively. Main TFE3 IHC issues were the low specificity (16/42, 38%), unreliable staining performance (15/42, 36%) and background staining (12/42, 29%). Most preferred IHC assays other than TFE3, cathepsin K and pancytokeratin were melan A (44/50, 88%), HMB45 (43/50, 86%), carbonic anhydrase IX (41/50, 82%) and CK7 (32/50, 64%). Cut-off for positive TFE3 fluorescent in situ hybridisation (FISH) was preferably 10% (9/50, 18%), although significant variation in cut-off values was present. 23/48 (48%) participants required TFE3 FISH testing to confirm TFE3-RCC regardless of the histomorphologic and IHC assessment. 28/50 (56%) participants would request additional molecular studies other than FISH assay in selected cases, whereas 3/50 participants use additional molecular cases in all cases when TFE3-RCC is in the differential.Optimal diagnostic approach on TFE3-RCC is impacted by IHC and/or FISH assay preferences as well as their conflicting interpretation methods. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  genitourinary pathology; immunohistochemistry; kidney neoplasms

Year:  2021        PMID: 33514585     DOI: 10.1136/jclinpath-2020-207372

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  3 in total

Review 1.  Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors.

Authors:  Wen-I Chang; Claire Lin; Nicholas Liguori; Joshua N Honeyman; Bradley DeNardo; Wafik El-Deiry
Journal:  Front Pharmacol       Date:  2022-01-20       Impact factor: 5.810

Review 2.  Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers.

Authors:  Die Qian; Lisha He; Qing Zhang; Wenqing Li; Dandan Tang; Chunjie Wu; Fei Yang; Ke Li; Hong Zhang
Journal:  Curr Oncol       Date:  2022-08-22       Impact factor: 3.109

Review 3.  Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors.

Authors:  Anna Caliò; Matteo Brunelli; Stefano Gobbo; Pedram Argani; Enrico Munari; George Netto; Guido Martignoni
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.